葡萄膜炎的治疗进展
Progress in the Treatment of Uveitis
DOI: 10.12677/ACM.2022.12121682, PDF,   
作者: 白旭旭：延安大学，陕西 延安；王理论：延安大学附属医院，陕西 延安
关键词: 葡萄膜炎；治疗；糖皮质激素；免疫抑制剂；生物制剂；基因治疗；RNA干扰；Uveitis； Treatment； Corticosteroids； Immunosuppressors； Biologics； Gene Therapy； RNA Interference
摘要: 本文旨在对葡萄膜炎的治疗方法进行总结和探讨。葡萄膜炎是一类常见眼科致盲疾病，病因复杂、种类繁多，发病机制涉及感染、自身免疫等多种机制且尚未完全阐明。通过参阅国内外相关文献发现，类固醇激素、免疫抑制剂、生物制剂药物是治疗葡萄膜炎的主要措施；随着医疗技术的进展，一些新型治疗手段比如基因治疗、RNA干扰等技术也将逐步用于葡萄膜炎的治疗。
Abstract: This paper aims to summarize and explore the treatment of uveitis. Uveitis is a kind of common ophthalmic blindness disease, with complex etiology and various types. The pathogenesis involves various mechanisms, such as infection and autoimmunity, and it has not been fully clarified. Through the relevant domestic and international literature, steroid hormones, immunosuppressants and biological agents are the main measures for the treatment of uveitis; with the progress of medical technology, some new treatment methods such as gene therapy and RNA interference will be gradually used in the treatment of uveitis.
文章引用：白旭旭, 王理论. 葡萄膜炎的治疗进展[J]. 临床医学进展, 2022, 12(12): 11674-11679. https://doi.org/10.12677/ACM.2022.12121682

参考文献

[1] 何宇, 石晶明. 葡萄膜炎的治疗进展[J]. 中国实用眼科杂志, 2012, 30(7): 765-768.
[2] London, N.J., Rathinam, S.R. and Cunningham, E.J. (2010) The Epidemiology of Uveitis in Developing Countries. International Ophthalmology Clinics, 50, 1-17. [Google Scholar] [CrossRef] 
[3] 郑曰忠. 重视葡萄膜炎药物治疗研究, 提高葡萄膜炎药物治疗效果[J]. 中华眼底病杂志, 2010(5): 404-408.
[4] 郑曰忠. 葡萄膜炎的临床治疗研究进展[J]. 中华眼科杂志, 2008(10): 952-955.
[5] 张传宏, 薛黎萍. 非感染性葡萄膜炎药物治疗进展[J]. 国际眼科纵览, 2021, 45(2): 89-98.
[6] Burkholder, B.M. and Jabs, D.A. (2021) Uveitis for the Non-Ophthalmologist. BMJ, 372, m4979. [Google Scholar] [CrossRef] [PubMed]
[7] 中华医学会眼科学分会眼免疫学组. 我国急性前葡萄膜炎临床诊疗专家共识(2016年) [J]. 中华眼科杂志, 2016, 52(3): 164-166.
[8] Gaudio, P. (2004) A Review of Evidence Guiding the Use of Corticosteroids in the Treatment of Intraocular Inflammation. Ocular Immunology and Inflammation, 12, 169-192. [Google Scholar] [CrossRef] [PubMed]
[9] Modorati, G. and Miserocchi, E. (2012) Intravitreal In-jection Therapy in the Treatment of Noninfectious Uveitis. Developments in Ophthalmology, 51, 110-121. [Google Scholar] [CrossRef] [PubMed]
[10] 宋佳忆, 陈婷, 艾明. 玻璃体腔注药治疗非感染性葡萄膜炎黄斑水肿的研究现状与进展[J]. 中华眼底病杂志, 2022, 38(5): 410-414.
[11] Sallam, A., Taylor, S.R., Habot-Wilner, Z., et al. (2012) Repeat Intravitreal Triamcinolone Acetonide Injections in Uveitic Macular Oedema. Acta Ophthalmologica, 90, e323-e325. [Google Scholar] [CrossRef] [PubMed]
[12] Jaffe, G.J., Foster, C.S., Pavesio, C.E., et al. (2019) Effect of an Injectable Fluocinolone Acetonide Insert on Recurrence Rates in Chronic Noninfectious Uveitis Affecting the Posterior Segment: Twelve-Month Results. Ophthalmology, 126, 601-610. [Google Scholar] [CrossRef] [PubMed]
[13] Bahadorani, S., Krambeer, C., Wannamaker, K., et al. (2018) The Effects of Repeated Ozurdex Injections on Ocular Hypertension. Clinical Ophthalmology, 12, 639-642. [Google Scholar] [CrossRef] 
[14] Mathis, T., Cerquaglia, A., Weber, M., et al. (2021) Uveitis Treated with Dexamethasone Implant. Retina, 41, 620-629. [Google Scholar] [CrossRef] 
[15] Wakefield, D., McCluskey, P., Wildner, G., et al. (2017) Inflammatory Eye Disease: Pre-Treatment Assessment of Patients Prior to Commencing Immunosuppressive and Bio-logic Therapy: Recommendations from an Expert Committee. Autoimmunity Reviews, 16, 213-222. [Google Scholar] [CrossRef] [PubMed]
[16] Gangaputra, S., Newcomb, C.W., Liesegang, T.L., et al. (2009) Methotrexate for Ocular Inflammatory Diseases. Ophthalmology, 116, 2188-2198. [Google Scholar] [CrossRef] [PubMed]
[17] Hatemi, G., Christensen, R., Bang, D., et al. (2018) 2018 Update of the EULAR Recommendations for the Management of Behcet’s Syndrome. Annals of Rheumatic Diseases, 77, 808-818. [Google Scholar] [CrossRef] [PubMed]
[18] Pasadhika, S., Kempen, J.H., Newcomb, C.W., et al. (2009) Azathioprine for Ocular Inflammatory Diseases. The American Journal of Ophthalmology, 148, 500-509. [Google Scholar] [CrossRef] [PubMed]
[19] Kim, E.C. and Foster, C.S. (2006) Immunomodulatory Therapy for the Treatment of Ocular Inflammatory Disease: Evidence-Based Medicine Recommendations for Use. International Ophthalmology Clinics, 46, 141-164. [Google Scholar] [CrossRef] [PubMed]
[20] Kacmaz, R.O., Kempen, J.H., Newcomb, C., et al. (2010) Cyclosporine for Ocular Inflammatory Diseases. Ophthalmology, 117, 576-584. [Google Scholar] [CrossRef] [PubMed]
[21] Zaghetto, J.M., Yamamoto, M.M., Souza, M.B., et al. (2010) Chlorambucil and Cyclosporine A in Brazilian Patients with Behcet’s Disease Uveitis: A Retrospective Study. Arquivos Brasileiros de Oftalmologia, 73, 40-46. [Google Scholar] [CrossRef] 
[22] 白琳, 杨培增. 白塞病葡萄膜炎的治疗与展望[J]. 中华实验眼科杂志, 2016, 34(8): 761-764.
[23] 樊帆, 周旻, 罗怡. 抗肿瘤坏死因子-α制剂治疗葡萄膜炎研究进展[J]. 中华眼科杂志, 2013, 49(3): 285-288.
[24] 张传宏, 胡淑娴, 潘燕婷, 等. 阿达木单抗治疗非感染性葡萄膜炎研究进展[J]. 国际眼科杂志, 2021, 21(9): 1561-1565.
[25] 彭宇, 邱新文, 叶波, 等. 阿达木单抗治疗非感染性葡萄膜炎[J]. 国际眼科纵览, 2022, 46(4): 336-340.
[26] Diaz-Llopis, M., Garcia-Delpech, S., Salom, D., et al. (2008) Adalimumab Therapy for Refractory Uveitis: A Pilot Study. Journal of Ocular Pharmacology and Therapeutics, 24, 351-361. [Google Scholar] [CrossRef] [PubMed]
[27] Suhler, E.B., Adán, A., Brézin, A.P., et al. (2018) Safety and Efficacy of Adalimumab in Patients with Noninfectious Uveitis in an Ongoing Open-Label Study: VISUAL III. Ophthalmology, 125, 1075-1087. [Google Scholar] [CrossRef] [PubMed]
[28] Burmester, G.R., Gordon, K.B., Rosenbaum, J.T., et al. (2020) Long-Term Safety of Adalimumab in 29,967 Adult Patients from Global Clinical Trials across Multiple Indications: An Updated Analysis. Advances in Therapy, 37, 364-380. [Google Scholar] [CrossRef] [PubMed]
[29] Srivastava, A., Rajappa, M. and Kaur, J. (2010) Uveitis: Mechanisms and Recent Advances in Therapy. Clinica Chimica Acta, 411, 1165-1171. [Google Scholar] [CrossRef] [PubMed]
[30] De Kozak, Y., Thillaye-Goldenberg, B., Naud, M.C., et al. (2002) Inhibition of Experimental Autoimmune Uveoretinitis by Systemic and Subconjunctival Adenovirus-Mediated Transfer of the Viral IL-10 Gene. Clinical & Experimental Immunology, 130, 212-223. [Google Scholar] [CrossRef] [PubMed]
[31] Trittibach, P., Barker, S.E., Broderick, C.A., et al. (2008) Lentiviral-Vector-Mediated Expression of Murine IL-1 Receptor Antagonist or IL-10 Reduces the Severity of Endo-toxin-Induced Uveitis. Gene Therapy, 15, 1478-1488. [Google Scholar] [CrossRef] [PubMed]
[32] Agarwal, R.K., Kang, Y., Zambidis, E., et al. (2000) Retroviral Gene Therapy with an Immunoglobulin-Antigen Fusion Construct Protects from Experimental Autoimmune Uveitis. Journal of Clinical Investigation, 106, 245-252. [Google Scholar] [CrossRef] 
[33] Shen, W.Y., Yu, M.J., Barry, C.J., et al. (1998) Expression of Cell Adhesion Molecules and Vascular Endothelial Growth Factor in Experimental Choroidal Neovascularisation in the Rat. British Journal of Ophthalmology, 82, 1063-1071. [Google Scholar] [CrossRef] [PubMed]
[34] van de Stolpe, A. and van der Saag, P.T. (1996) Intercellular Adhesion Molecule-1. Journal of Molecular Medicine (Berlin), 74, 13-33. [Google Scholar] [CrossRef] 
[35] Hirano, Y., Sakurai, E., Matsubara, A., et al. (2010) Suppression of ICAM-1 in Retinal and Choroidal Endothelial Cells by Plasmid Small-Interfering RNAs in Vivo. Investigative Oph-thalmology & Visual Science, 51, 508-515. [Google Scholar] [CrossRef] [PubMed]
[36] Hou, Y., Xing, L., Fu, S., et al. (2009) Down-Regulation of Inducible Co-Stimulator (ICOS) by Intravitreal Injection of Small Interfering RNA (siRNA) Plasmid Suppresses Ongoing Ex-perimental Autoimmune Uveoretinitis in Rats. Graefe’s Archive for Clinical and Experimental Ophthalmology, 247, 755-765. [Google Scholar] [CrossRef] [PubMed]

为你推荐